News and Trends 15 Dec 2022 Charcot-Marie-Tooth study to get $250K grant The Muscular Dystrophy Association (MDA) and Charcot-Marie-Tooth Research Foundation (CMTRF) have announced joint funding for a study by Alessandra Bolino at San Raffaele Hospital (Ospedale San Raffaele), Italy, on restoring membrane trafficking in Charcot-Marie-Tooth (CMT) neuropathies with aberrant myelin. This will be a three-year study, with the grant totaling $263,450. “We at the Muscular Dystrophy […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation Myrtelle Inc., a clinical stage gene therapy company, has announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product candidate for the treatment of Canavan disease (CD). EMA OD designation’s aim is to encourage the development of treatments for life-threatening rare conditions by providing […] December 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Solve Therapeutics launches to tackle cancer Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company’s formation reunites the former VelosBio Inc. team. SolveTx is fully operational with more than 25 employees and is actively pursuing discovery and development efforts at its 10,000-square-foot laboratory in San Diego. Solve […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Cyclica and SK Chemicals to co-develop novel therapeutics Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Replay targets genetic brain disorders with new gene therapy company, Kaleibe Replay, a genome writing company, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders. It is the third of Replay’s product companies to launch since the company’s formation in July and will leverage Replay’s high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, to target genetic brain disorders. […] December 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 STORM Therapeutics closes $30M Series B financing STORM Therapeutics Ltd., which is working on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has successfully completed a $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital (CIC) and new investors […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 NMD Pharma cleared for spinal muscular atrophy trial NMD Pharma A/S has received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to advance NMD670 into a phase II clinical study in patients of spinal muscular atrophy (SMA) type 3. NMD Pharma is a Danish clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 ImaginAb launches trial to study neoadjuvant immunotherapy ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety of neoadjuvant immune checkpoint inhibitor treatment of stage III surgically resectable melanoma through use of CD8 ImmunoPET. ImaginAb is a global biotechnology company focused on […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Etcembly reveals breakthrough in optimizing TCR assets Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 PrecisionLife to work on R&D with Ono Pharmaceutical PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 PhoreMost and ThinkCyte collaborate on AI-based drug discovery PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Asieris doses first patient in bladder cancer diagnostic trial Asieris Pharmaceuticals has announced that Hexvix, a drug used for bladder cancer diagnosis, completed dosing for the first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch. Hexvix has been approved in the U.S. and many European countries. The combined use of Hexvix and blue light cystoscopy (BLC) for the management of […] December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email